CNSL.L

Cambridge Nutritional Sciences
Cambridge Nutrition. - Directorate Change
13th August 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 1512A
Cambridge Nutritional Sciences PLC
13 August 2024
 

Cambridge Nutritional Sciences plc

 

(the "Company" or "CNSL")

 

Directorate Change

 

 

 

Cambridge Nutritional Sciences plc (AIM:CNSL), the specialist medical diagnostics company focused on industry-leading Health and Nutrition products, announces that James Cooper, currently Chief Operating Officer, has been appointed as interim Chief Executive Officer of CNSL with immediate effect. After two years as CEO, and thirteen years with the Company, Jag Grewal has tendered his resignation and stepped down from the Board with immediate effect.

 

Jag will continue to work with the Board to effect an orderly handover.

 

In his brief tenure as COO, James has demonstrated a wide range of operational and management skills and the Board is confident he will be a very capable interim CEO.

 

Cally Rand, Chair of CNSL , said:

 

"Jag has been an integral part of the business over the last thirteen years and has managed the business extremely well as CNSL has transitioned away from infectious disease diagnostics.   I would also like to extend my sincere thanks to Jag for the huge role he has played in the foundation and development of this Company. On behalf of the entire Board, we wish him the best for the future"

 

Jag Grewal commented:

 

"I have deeply enjoyed leading CNS plc and working alongside such a dedicated and talented team and supportive Board.  I want to express my deepest gratitude to the Board, our leadership team, and all of our employees for their support, collaboration and hard work during my tenure.  I am confident that the Company is in a strong position to continue its trajectory of growth and success."

 

 

 

Contacts: 

Cambridge Nutritional Sciences PLC           

www.cnsplc.com

Cally Rand Executive Chair




Cavendish Capital Markets Limited    

Tel: 020 7220 0500

Geoff Nash / Edward Whiley / (Corporate Finance)


Nigel Birks / Harriet Ward (ECM)






About Cambridge Nutritional Sciences plc

Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (MAR) as in force in the United Kingdom pursuant to the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via Regulatory Information Service (RIS), this inside information is now considered to be in the public domain.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAGPURWRUPCGQP]]>
TwitterFacebookLinkedIn